July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
DARC (Detection of Apoptosing Retinal Cells) as a means for early detection of retinal neuronal damage, and how that can lead to a change in diagnosis and treatment
Author Affiliations & Notes
  • M Francesca Cordeiro
    Glaucoma & Retinal Neurodegnrtn Res Grp, UCL Inst Ophthal & Western Eye Hsp London, London, United Kingdom
    Surgery, Imperial College London, LONDON, United Kingdom
  • Footnotes
    Commercial Relationships   M Francesca Cordeiro, Allergan (R), Annexon (F), Novartis (R), Santen (F), Sooft (R), Thea (R), UCL (P)
  • Footnotes
    Support  Wellcome Trust WT099729
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2581. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M Francesca Cordeiro; DARC (Detection of Apoptosing Retinal Cells) as a means for early detection of retinal neuronal damage, and how that can lead to a change in diagnosis and treatment. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2581.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : DARC (Detection of Apoptosing Retinal Cells) is a non-invasive real-time imaging technique using confocal laser scanning ophthalmoscopy to visualise single retinal nerve cell apoptosis in vivo through the use of an intravenously administered fluorescent biomarker ANX776.
Recent Phase 1 results suggest it may be a new clinical tool with which to diagnose and identify patients with early and progressing glaucoma, before they lose vision. Furthermore, indications that it predicted future disease progression suggest it may serve as a surrogate biomarker, providing rapid information that could reduce the duration of glaucoma clinical studies, although these findings need to be validated. Phase II trials currently in the analysis stage, have been performed in optic neuritis, Down’s syndrome, and age-related macular degeneration, in addition to glaucoma, to investigate DARC for other indications. Since DARC has been used to successfully assess neuroprotective drugs experimentally in different models of neurodegeneration, it is hoped it can be translated to the clinic to provide a real-time and objective method by which to monitor not only progression of retinal neuronal disease but also response to treatment.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×